Kaicheng Wang, MD, MPH
Cards
About
Research
Publications
2023
Prior cycles of anti-CD20 antibodies affect antibody responses after repeated SARS-CoV-2 mRNA vaccination
Asashima H, Kim D, Wang K, Lele N, Buitrago-Pocasangre N, Lutz R, Cruz I, Raddassi K, Ruff W, Racke M, Wilson J, Givens T, Grifoni A, Weiskopf D, Sette A, Kleinstein S, Montgomery R, Shaw A, Li F, Fan R, Hafler D, Tomayko M, Longbrake E. Prior cycles of anti-CD20 antibodies affect antibody responses after repeated SARS-CoV-2 mRNA vaccination. JCI Insight 2023, 8: e168102. PMID: 37606046, PMCID: PMC10543713, DOI: 10.1172/jci.insight.168102.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 mRNA vaccinationB-cell-depleted patientsB-cell depletionAntibody responseMRNA vaccinationThird doseCell depletionT cellsClaude D. Pepper Older Americans Independence CenterB cellsNational Multiple Sclerosis SocietyAnti-CD20 antibodySpike-specific antibodiesMultiple Sclerosis SocietyLow cumulative exposureLogistic regression modelsImportant clinical needCD20 therapyCD20 treatmentMost patientsThird vaccineSerologic responseVaccine dosesMRNA vaccinesVaccination strategiesChanges in opioid prescribing in veterans with headache during the COVID‐19 pandemic: A regression discontinuity in time analysis
Wang K, Fenton B, Skanderson M, Black A, Becker W, Seng E, Anthony S, Guirguis A, Altalib H, Kimber A, Lorenze N, Scholten J, Graham G, Sandbrink F, Sico J. Changes in opioid prescribing in veterans with headache during the COVID‐19 pandemic: A regression discontinuity in time analysis. Headache The Journal Of Head And Face Pain 2023, 63: 1295-1303. PMID: 37596904, DOI: 10.1111/head.14605.Peer-Reviewed Original ResearchMorphine equivalent daily dosesVeterans Health AdministrationNumber of prescriptionsOpioid prescribingOpioid prescriptionsLong-term opioid therapyMME/dayRetrospective cohort studyEquivalent daily dosesCOVID-19 pandemicOpioid therapyPre-pandemic periodCohort studyDaily doseChronic painOutpatient visitsPrevious diagnosisDaily dosesMean ageSubgroup analysisHeadache disordersOpioid accessHealth AdministrationPrescribingCoronavirus diseaseTrajectory of blood pressure after initiating anti-calcitonin gene-related peptide treatment of migraine: a target trial emulation from the veterans health administration
Wang K, Fenton B, Dao V, Guirguis A, Anthony S, Skanderson M, Sico J. Trajectory of blood pressure after initiating anti-calcitonin gene-related peptide treatment of migraine: a target trial emulation from the veterans health administration. The Journal Of Headache And Pain 2023, 24: 108. PMID: 37582724, PMCID: PMC10426172, DOI: 10.1186/s10194-023-01640-y.Peer-Reviewed Original ResearchConceptsAnti-CGRP treatmentVeterans Health AdministrationBlood pressureBP changesHealth AdministrationDiastolic BP changesExacerbation of hypertensionNumber of antihypertensivesIncidence of hypertensionHigher healthcare utilizationSystolic BP changeKaplan-Meier curvesBlood pressure readingsGene-related peptideTarget trial emulationYears of treatmentBlood pressure regulationHigh-quality real-world evidenceReal-world evidenceMixed-effects Poisson modelsChronic migraine diagnosisInverse probability weightsAntihypertension medicationsAntihypertensive medicationsBaseline hypertensionCalcitonin Gene–Related Peptide Monoclonal Antibodies and Risk of SARS-CoV-2 Infection and Severe COVID-19 Outcomes Among Veterans With Migraine Disorder
Wang K, Fenton B, Deng Y, Anthony S, Dao V, Schindler E, Lipton R, Guirguis A, Skanderson M, Seng E, Sico J. Calcitonin Gene–Related Peptide Monoclonal Antibodies and Risk of SARS-CoV-2 Infection and Severe COVID-19 Outcomes Among Veterans With Migraine Disorder. JAMA Network Open 2023, 6: e2326371. PMID: 37523183, PMCID: PMC10391301, DOI: 10.1001/jamanetworkopen.2023.26371.Peer-Reviewed Original ResearchConceptsCalcitonin gene-related peptideSARS-CoV-2 infectionSevere COVID-19 outcomesCGRP mAbsMechanical ventilationSupplemental oxygenCOVID-19 outcomesSARS-CoV-2Cohort studyCGRP antagonistMAIN OUTCOMEMigraine disordersPositive SARS-CoV-2 test resultSARS-CoV-2 test resultsCOVID-19Protocol hazard ratiosRetrospective cohort studyMonoclonal antibody treatmentGene-related peptideLikelihood of hospitalizationCourse of diseasePeptide monoclonal antibodyElectronic health recordsNeuroimmune modulatorCumulative incidence
2022
Impact of Drug Exposure on Resistance Selection Following Artemether‐Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda
Kay K, Goodwin J, Ehrlich H, Ou J, Freeman T, Wang K, Li F, Wade M, French J, Huang L, Aweeka F, Mwebaza N, Kajubi R, Riggs M, Ruiz‐Garcia A, Parikh S. Impact of Drug Exposure on Resistance Selection Following Artemether‐Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda. Clinical Pharmacology & Therapeutics 2022, 113: 660-669. PMID: 36260349, PMCID: PMC9981240, DOI: 10.1002/cpt.2768.Peer-Reviewed Original ResearchConceptsLopinavir-ritonavirLumefantrine concentrationsSensitive parasitesRecurrence riskPopulation PK/PD modelArtemether-lumefantrine treatmentTrimethoprim-sulfamethoxazole prophylaxisPK/PD modelPopulation PK modelFirst-order absorptionHigh transmission regionsAntiretroviral regimensLumefantrine exposureLumefantrine susceptibilityPfcrt K76Pfmdr1 N86Suboptimal dosingArtemether-lumefantrineTwo-compartment modelHIV statusRecurrent infectionsCombination therapyDrug exposurePrimary treatmentArtemisinin resistanceFrequency, Demographics, Comorbidities, and Health Care Utilization by Veterans With Migraine
Seng EK, Fenton BT, Wang K, Lipton RB, Ney J, Damush T, Grinberg AS, Skanderson M, Sico JJ. Frequency, Demographics, Comorbidities, and Health Care Utilization by Veterans With Migraine. Neurology 2022, 99: e1979-e1992. PMID: 36100439, PMCID: PMC9651466, DOI: 10.1212/wnl.0000000000200888.Peer-Reviewed Original ResearchConceptsVeterans Health AdministrationHealth care utilizationStudy periodCare utilizationHealth AdministrationOne-year period prevalenceOverweight/obesityMental health disordersChi-square testStudent's t-testMilitary sexual traumaAnnual encountersHeadache comorbidityPain comorbiditiesCohort entryCommon comorbiditiesPain disordersTotal cohortAnnual incidenceHealthcare utilizationHigher proportionPeriod prevalenceEmergency departmentMigraine carePrimary careCharacteristics and Gender Differences of Headache in the Veterans Health Administration
Sico JJ, Seng E, Wang K, Skanderson M, Schindler E, Ney JP, Lorenze N, Kimber A, Lindsey H, Grinberg AS, Kuruvilla D, Higgins D, Graham G, Sandbrink F, Scholten J, Shapiro RE, Lipton RB, Fenton B. Characteristics and Gender Differences of Headache in the Veterans Health Administration. Neurology 2022, 99: e1993-e2005. PMID: 36100437, PMCID: PMC9651459, DOI: 10.1212/wnl.0000000000200905.Peer-Reviewed Original ResearchConceptsVeterans Health AdministrationHeadache diagnosisHealthcare utilizationIncidence rateHeadache careHeadache typesHealth AdministrationSociodemographic characteristicsMilitary-related exposuresAge-adjusted incidenceEmergency department utilizationElectronic health record dataRetrospective cohort designType of headacheHigh incidence rateTraumatic brain injuryUnited States veteransHealth record dataPost-traumatic stress disorderGender differencesMilitary sexual traumaHeadache disordersBrain injuryHeadache specialistsCohort designThe Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial
Whalen ME, Kajubi R, Goodwin J, Orukan F, Colt M, Huang L, Richards K, Wang K, Li F, Mwebaza N, Aweeka FT, Parikh S. The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial. Clinical Infectious Diseases 2022, 76: 443-452. PMID: 36130191, PMCID: PMC9907485, DOI: 10.1093/cid/ciac783.Peer-Reviewed Original ResearchConceptsArtemether-lumefantrineReinfection riskArtemisinin-based combination therapyDay 7 levelsOverall drug exposureHigh transmission settingsYoung childrenAntimalarial exposureUncomplicated malariaExtended regimenRecurrent parasitemiaControlled TrialsPrimary outcomeCombination therapyKaplan-MeierDrug exposureTotal episodesUgandan childrenArtemisinin resistanceLumefantrine concentrationsPharmacodynamic studiesHigh riskPharmacokinetic parametersRecurrence riskDay 7A Composite End Point of Graft Status and eGFR at 1 Year to Improve the Scientific Registry of Transplant Recipients’ Five-Tier Rating System
Wang K, Deng Y, Stewart D, Formica R. A Composite End Point of Graft Status and eGFR at 1 Year to Improve the Scientific Registry of Transplant Recipients’ Five-Tier Rating System. Journal Of The American Society Of Nephrology 2022, 33: 1613-1624. PMID: 35537779, PMCID: PMC9342646, DOI: 10.1681/asn.2022010078.Peer-Reviewed Original ResearchConceptsComposite end pointTraditional end pointsTransplant programsEnd pointAllograft functionGraft survivalScientific RegistryFive-tier systemLong-term graft outcomeDonor graft survivalKidney transplant programAllograft failureAllograft survivalGraft outcomeTransplant recipientsGraft statusGraft failureEGFR differenceSRTR dataSurvival rateEGFRSurvivalRegistryMeaningful differencesConcept studyMotivational interviewing to enhance psychosocial treatment attendance in people with SMI
Fiszdon JM, Choi J, Wang K, Parente LT, Hallinan S, Burton E, Bell MD, Martino S. Motivational interviewing to enhance psychosocial treatment attendance in people with SMI. Schizophrenia Research 2022, 246: 165-171. PMID: 35779328, DOI: 10.1016/j.schres.2022.06.015.Peer-Reviewed Original ResearchConceptsMotivational interviewingTreatment attendanceControl interviewTraining sessionsCognitive training sessionsLevel of motivationCognitive trainingGeneral psychiatric symptomsPsychosocial interventionsTraining tasksHigher IQLack of motivationCI interventionMotivation levelsMI interventionCognitive impairmentMI conditionPsychiatric symptomsFull sampleInitial engagementParticipantsSessionsMotivationInterventionTraining